Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics

Abstract Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess heterogeneity that exists among multiple metastatic lesions throughout the treatment...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Allen Li, Jamie M. Keck, Swapnil Parmar, Janice Patterson, Marilyne Labrie, Allison L. Creason, Brett E. Johnson, Molly Downey, George Thomas, Carol Beadling, Laura M. Heiser, Annette Kolodzie, Alexander R. Guimaraes, Christopher L. Corless, Joe W. Gray, Gordon B. Mills, Raymond C. Bergan, Zahi I. Mitri
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8c98543d96874c89b755cdec2ccf84d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c98543d96874c89b755cdec2ccf84d0
record_format	dspace
spelling	oai:doaj.org-article:8c98543d96874c89b755cdec2ccf84d02021-12-02T16:35:52ZCharacterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics10.1038/s41698-021-00165-42397-768Xhttps://doaj.org/article/8c98543d96874c89b755cdec2ccf84d02021-03-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00165-4https://doaj.org/toc/2397-768XAbstract Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess heterogeneity that exists among multiple metastatic lesions throughout the treatment course. We developed a precision oncology platform that combines serial biopsies, multi-omic analysis, longitudinal patient monitoring, and molecular tumor boards, with the goal of improving cancer management through enhanced understanding of the entire cancer ecosystem within each patient. We describe this integrative approach using comprehensive analytics generated from serial-biopsied lesions in a metastatic breast cancer patient. The serial biopsies identified remarkable heterogeneity among metastatic lesions that presented clinically as discordance in receptor status and genomic alterations with mixed treatment response. Based on our study, we highlight clinical scenarios, such as rapid progression or mixed response, that indicate consideration for repeat biopsies to evaluate intermetastatic heterogeneity (IMH), with the objective of refining targeted therapy. We present a framework for understanding the clinical significance of heterogeneity in breast cancer between metastatic lesions utilizing multi-omic analyses of serial biopsies and its implication for effective personalized treatment.Allen LiJamie M. KeckSwapnil ParmarJanice PattersonMarilyne LabrieAllison L. CreasonBrett E. JohnsonMolly DowneyGeorge ThomasCarol BeadlingLaura M. HeiserAnnette KolodzieAlexander R. GuimaraesChristopher L. CorlessJoe W. GrayGordon B. MillsRaymond C. BerganZahi I. MitriNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Allen Li Jamie M. Keck Swapnil Parmar Janice Patterson Marilyne Labrie Allison L. Creason Brett E. Johnson Molly Downey George Thomas Carol Beadling Laura M. Heiser Annette Kolodzie Alexander R. Guimaraes Christopher L. Corless Joe W. Gray Gordon B. Mills Raymond C. Bergan Zahi I. Mitri Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
description	Abstract Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess heterogeneity that exists among multiple metastatic lesions throughout the treatment course. We developed a precision oncology platform that combines serial biopsies, multi-omic analysis, longitudinal patient monitoring, and molecular tumor boards, with the goal of improving cancer management through enhanced understanding of the entire cancer ecosystem within each patient. We describe this integrative approach using comprehensive analytics generated from serial-biopsied lesions in a metastatic breast cancer patient. The serial biopsies identified remarkable heterogeneity among metastatic lesions that presented clinically as discordance in receptor status and genomic alterations with mixed treatment response. Based on our study, we highlight clinical scenarios, such as rapid progression or mixed response, that indicate consideration for repeat biopsies to evaluate intermetastatic heterogeneity (IMH), with the objective of refining targeted therapy. We present a framework for understanding the clinical significance of heterogeneity in breast cancer between metastatic lesions utilizing multi-omic analyses of serial biopsies and its implication for effective personalized treatment.
format	article
author	Allen Li Jamie M. Keck Swapnil Parmar Janice Patterson Marilyne Labrie Allison L. Creason Brett E. Johnson Molly Downey George Thomas Carol Beadling Laura M. Heiser Annette Kolodzie Alexander R. Guimaraes Christopher L. Corless Joe W. Gray Gordon B. Mills Raymond C. Bergan Zahi I. Mitri
author_facet	Allen Li Jamie M. Keck Swapnil Parmar Janice Patterson Marilyne Labrie Allison L. Creason Brett E. Johnson Molly Downey George Thomas Carol Beadling Laura M. Heiser Annette Kolodzie Alexander R. Guimaraes Christopher L. Corless Joe W. Gray Gordon B. Mills Raymond C. Bergan Zahi I. Mitri
author_sort	Allen Li
title	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
title_short	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
title_full	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
title_fullStr	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
title_full_unstemmed	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
title_sort	characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8c98543d96874c89b755cdec2ccf84d0
work_keys_str_mv	AT allenli characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT jamiemkeck characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT swapnilparmar characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT janicepatterson characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT marilynelabrie characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT allisonlcreason characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT brettejohnson characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT mollydowney characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT georgethomas characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT carolbeadling characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT lauramheiser characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT annettekolodzie characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT alexanderrguimaraes characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT christopherlcorless characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT joewgray characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT gordonbmills characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT raymondcbergan characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics AT zahiimitri characterizingadvancedbreastcancerheterogeneityandtreatmentresistancethroughserialbiopsiesandcomprehensiveanalytics
_version_	1718383704120754176

Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics

Ejemplares similares